Aotearoa Immunisation Register (AIR) FHIR Implementation Guide
2.1.0 - release New Zealand

Aotearoa Immunisation Register (AIR) FHIR Implementation Guide - Local Development build (v2.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

## ValueSet: AIR Vaccine Product

Official URL: https://nzhts.digital.health.nz/fhir/ValueSet/air-vaccine-product-code | Version: 2.1.0
Active as of 2026-07-21 | Computable Name: AIRVaccineProductCode

Allowable values for CVX and NZVX codes used to populate the vaccineCode element in an AIR Immunization resource.

References

- AIR Immunization
- AIR Immunization Recommendation

### Logical Definition (CLD)

This value set includes codes based on the following rules:

- Include these codes as defined in `http://hl7.org/fhir/sid/cvx` version Not Stated (use latest from terminology server)

  Code | Display
  03 | MMR
  05 | Measles
  06 | Rubella
  08 | HepB
  09 | Td
  10 | IPV
  19 | BCG
  20 | DTaP
  21 | VV
  22 | DTP-Hib
  25 | Typhoid
  26 | Cholera
  28 | DT
  30 | HBIG
  33 | 23PPV
  35 | Tetanus
  37 | YFV
  39 | JEV
  43 | HepB
  44 | HepB
  48 | Hib
  50 | DTaP-Hib
  51 | Hib-HepB
  52 | HepA
  56 | Dengue
  62 | HPV4
  75 | MPX
  83 | HepA
  100 | PCV7
  101 | Typhoid
  103 | MenC
  104 | HepB-HepA
  110 | DTaP-IPV-HepB
  114 | MenACWY
  115 | Tdap
  116 | RV5
  118 | HPV2
  119 | RV1
  120 | DTaP-IPV-Hib
  121 | rZV
  127 | Influenza A (H1N1)
  130 | DTaP-IPV
  133 | PCV13
  134 | JEV
  150 | Influenza
  160 | Influenza A (H5N1)
  161 | Influenza
  163 | MenB
  165 | HPV9
  182 | OPV
  187 | rZV
  202 | Influenza
  205 | Influenza
  208 | COVID-19 mRNA-CV (30mcg)
  210 | COVID-19 ChAd-CV
  211 | COVID-19 rCV
  217 | COVID-19 mRNA-CV (30mcg)
  218 | COVID-19 mRNA-CV (10mcg)
  219 | COVID-19 mRNA-CV (3mcg)
  222 | TBE
  300 | COVID-19 mRNA-CV (15mcg/15mcg)
  303 | RSV
  93 | RSV
  500 | COVID-19 Product Unspecified
  316 | MenABCWY
  01 | DTP
  17 | Hib, unspecified
  89 | Polio, unspecified
  198 | DTP-HepB-Hib
  122 | RV, unspecified
  148 | MenC/Y-Hib PRP
  167 | Meningococcal
  191 | MenA
  192 | MenAC
  215 | PCV15
  216 | PCV20
  327 | PCV21
  04 | M/R
  94 | MMRV
  324 | fIPV

- Include all codes defined in `https://standards.digital.health.nz/ns/immunisation-code` version 📦2.1.0

### Expansion

Expansion from tx.fhir.org based on:

- codesystem Vaccine Administered Code Set (CVX) version 20250715
- codesystem NZVX Immunisation Code v2.1.0 (CodeSystem)

This value set contains 99 concepts

System | Code | Display (en) | JSON | XML
`http://hl7.org/fhir/sid/cvx` | 03 | MMR |  |
`http://hl7.org/fhir/sid/cvx` | 05 | measles |  |
`http://hl7.org/fhir/sid/cvx` | 06 | rubella |  |
`http://hl7.org/fhir/sid/cvx` | 08 | Hep B, adolescent or pediatric |  |
`http://hl7.org/fhir/sid/cvx` | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed |  |
`http://hl7.org/fhir/sid/cvx` | 10 | IPV |  |
`http://hl7.org/fhir/sid/cvx` | 19 | BCG |  |
`http://hl7.org/fhir/sid/cvx` | 20 | DTaP |  |
`http://hl7.org/fhir/sid/cvx` | 21 | varicella |  |
`http://hl7.org/fhir/sid/cvx` | 22 | DTP-Hib |  |
`http://hl7.org/fhir/sid/cvx` | 25 | typhoid, oral |  |
`http://hl7.org/fhir/sid/cvx` | 26 | cholera, unspecified formulation |  |
`http://hl7.org/fhir/sid/cvx` | 28 | DT (pediatric) |  |
`http://hl7.org/fhir/sid/cvx` | 30 | HBIG |  |
`http://hl7.org/fhir/sid/cvx` | 33 | pneumococcal polysaccharide PPV23 |  |
`http://hl7.org/fhir/sid/cvx` | 35 | tetanus toxoid, adsorbed |  |
`http://hl7.org/fhir/sid/cvx` | 37 | yellow fever live |  |
`http://hl7.org/fhir/sid/cvx` | 39 | Japanese encephalitis SC |  |
`http://hl7.org/fhir/sid/cvx` | 43 | Hep B, adult |  |
`http://hl7.org/fhir/sid/cvx` | 44 | Hep B, high-dosage, dialysis or IC |  |
`http://hl7.org/fhir/sid/cvx` | 48 | Hib (PRP-T) |  |
`http://hl7.org/fhir/sid/cvx` | 50 | DTaP-Hib |  |
`http://hl7.org/fhir/sid/cvx` | 51 | Hib-Hep B |  |
`http://hl7.org/fhir/sid/cvx` | 52 | Hep A, adult |  |
`http://hl7.org/fhir/sid/cvx` | 56 | dengue fever tetravalent |  |
`http://hl7.org/fhir/sid/cvx` | 62 | HPV, quadrivalent |  |
`http://hl7.org/fhir/sid/cvx` | 75 | Vaccinia (smallpox, mpox), live |  |
`http://hl7.org/fhir/sid/cvx` | 83 | Hep A, ped/adol, 2 dose |  |
`http://hl7.org/fhir/sid/cvx` | 100 | pneumococcal conjugate PCV 7 |  |
`http://hl7.org/fhir/sid/cvx` | 101 | typhoid, ViCPs |  |
`http://hl7.org/fhir/sid/cvx` | 103 | meningococcal C conjugate |  |
`http://hl7.org/fhir/sid/cvx` | 104 | Hep A-Hep B |  |
`http://hl7.org/fhir/sid/cvx` | 110 | DTaP-Hep B-IPV |  |
`http://hl7.org/fhir/sid/cvx` | 114 | meningococcal MCV4P |  |
`http://hl7.org/fhir/sid/cvx` | 115 | Tdap |  |
`http://hl7.org/fhir/sid/cvx` | 116 | rotavirus, pentavalent |  |
`http://hl7.org/fhir/sid/cvx` | 118 | HPV, bivalent |  |
`http://hl7.org/fhir/sid/cvx` | 119 | rotavirus, monovalent |  |
`http://hl7.org/fhir/sid/cvx` | 120 | DTaP-Hib-IPV |  |
`http://hl7.org/fhir/sid/cvx` | 121 | zoster live |  |
`http://hl7.org/fhir/sid/cvx` | 127 | Novel influenza-H1N1-09 |  |
`http://hl7.org/fhir/sid/cvx` | 130 | DTaP-IPV |  |
`http://hl7.org/fhir/sid/cvx` | 133 | Pneumococcal conjugate PCV 13 |  |
`http://hl7.org/fhir/sid/cvx` | 134 | Japanese Encephalitis IM |  |
`http://hl7.org/fhir/sid/cvx` | 150 | Influenza, split virus, quadrivalent, PF |  |
`http://hl7.org/fhir/sid/cvx` | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 |  |
`http://hl7.org/fhir/sid/cvx` | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric |  |
`http://hl7.org/fhir/sid/cvx` | 163 | meningococcal B, OMV |  |
`http://hl7.org/fhir/sid/cvx` | 165 | HPV9 |  |
`http://hl7.org/fhir/sid/cvx` | 182 | OPV, Unspecified |  |
`http://hl7.org/fhir/sid/cvx` | 187 | zoster recombinant |  |
`http://hl7.org/fhir/sid/cvx` | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative |  |
`http://hl7.org/fhir/sid/cvx` | 205 | Influenza, adjuvanted, quadrivalent, PF |  |
`http://hl7.org/fhir/sid/cvx` | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |  |
`http://hl7.org/fhir/sid/cvx` | 210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |  |
`http://hl7.org/fhir/sid/cvx` | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |  |
`http://hl7.org/fhir/sid/cvx` | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |  |
`http://hl7.org/fhir/sid/cvx` | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |  |
`http://hl7.org/fhir/sid/cvx` | 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |  |
`http://hl7.org/fhir/sid/cvx` | 222 | Tick-borne encephalitis, unspecified |  |
`http://hl7.org/fhir/sid/cvx` | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose |  |
`http://hl7.org/fhir/sid/cvx` | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF |  |
`http://hl7.org/fhir/sid/cvx` | 93 | RSV-MAb |  |
`http://hl7.org/fhir/sid/cvx` | 500 | COVID-19 Non-US Vaccine, Product Unknown |  |
`http://hl7.org/fhir/sid/cvx` | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF |  |
`http://hl7.org/fhir/sid/cvx` | 01 | DTP |  |
`http://hl7.org/fhir/sid/cvx` | 17 | Hib, unspecified formulation |  |
`http://hl7.org/fhir/sid/cvx` | 89 | polio, unspecified formulation |  |
`http://hl7.org/fhir/sid/cvx` | 198 | DTP-hepB-Hib Pentavalent Non-US |  |
`http://hl7.org/fhir/sid/cvx` | 122 | rotavirus, unspecified formulation |  |
`http://hl7.org/fhir/sid/cvx` | 148 | Meningococcal C/Y-HIB PRP |  |
`http://hl7.org/fhir/sid/cvx` | 167 | meningococcal, unknown serogroups |  |
`http://hl7.org/fhir/sid/cvx` | 191 | meningococcal A polysaccharide (non-US) |  |
`http://hl7.org/fhir/sid/cvx` | 192 | meningococcal AC polysaccharide (non-US) |  |
`http://hl7.org/fhir/sid/cvx` | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF |  |
`http://hl7.org/fhir/sid/cvx` | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF |  |
`http://hl7.org/fhir/sid/cvx` | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF |  |
`http://hl7.org/fhir/sid/cvx` | 04 | M/R |  |
`http://hl7.org/fhir/sid/cvx` | 94 | MMRV |  |
`http://hl7.org/fhir/sid/cvx` | 324 | Poliovirus, inactivated, fractional-dose (fIPV) |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 52101 | HepA-Typhoid |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 090306 | PCV unspecified |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 90906 | Td |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99001 | DTaP-IPV |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99002 | MeNZB |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99003 | Diphtheria, paed |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99004 | aP |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99005 | Diphtheria, adult |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99006 | Influenza |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99007 | HepA |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99008 | MenACWY |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99009 | Rabies |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99010 | RIG |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99011 | Tdap-IPV |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99012 | Tdap |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 99013 | MenC |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 210307 | DTaP-IPV-HepB/Hib |  |
`https://standards.digital.health.nz/ns/immunisation-code` | 260209 | PCV10 |  |
`https://standards.digital.health.nz/ns/immunisation-code` | EVPMnC | MenC |  |

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code